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SincetheﬁrstdescriptionofParkinson’sdisease(PD)nearlytwocenturiesago,anumberofstudieshaverevealedtheclinicalsymp-
toms, pathology, and therapeutic approaches to overcome this intractable neurodegenerative disease. 1-methy-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) are neurotoxins which produce Parkinsonian pathology. From
the animal studies using these neurotoxins, it has become well established that oxidative stress is a primary cause of, and essential
for, cellular apoptosis in dopaminergic neurons. Here, we describe the mechanism whereby oxidative stress evokes irreversible cell
death, and propose a novel therapeutic strategy for PD using molecular hydrogen. Hydrogen has an ability to reduce oxidative
damage and ameliorate the loss of nigrostriatal dopaminergic neuronal pathway in two experimental animal models. Thus, it is
strongly suggested that hydrogen might provide a great advantage to prevent or minimize the onset and progression of PD.
1.Introduction
The central pathological feature of PD was loss of neurons in
substantia nigra pars compacta (SNpc). DA depletion by the
loss of dopaminergic neurons in SNpc is a primary symptom
of PD [1]. PD is one of the most common neurodegenerative
and progressive diseases, along with Alzheimer’s disease
(AD) [2, 3]. In these last two decades, many lines of evidence
have emerged to suggest that oxidative stress is closely related
to the onset and the progression of PD and AD.
Using neurotoxins in experimental animal models, an
enormous number of studies have been undertaken to
developneuroprotectivedrugsagainstPD.MPTP(1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine) was found to be a by-
product of the chemical synthesis of a meperidine analog
with potent heroin-like eﬀects [4, 5]. MPTP has the ability
to induce PD-like pathology and has been used in var-
ious species including nonhuman primates, and rodents.
Among the neurotoxic mechanism of MPTP, mitochondrial
impairment is highly associated with oxidative damage and
related neurodegeneration; the detailed mechanism and the
linkage between oxidative damage and neurodegeneration
are discussed in this review. Although MPTP-induced PD
model animals are regarded as the best reproducible model,
another neurotoxin, 6-hydroxydopamine (6-OHDA; 2,4,5-
trihydroxyphenylethylamine), is also used for toxin-induced
a n i m a lm o d e lo fP D[ 6].
Many trials have focused on the reduction of oxidative
stress as a therapeutic strategy because oxidative stress is
regarded as one of the major risk factors in the onset of
PD as mentioned above. However, there are still no known
antioxidant drugs which are clinically used to prevent PD.
Here, the neurotoxic mechanism of MPTP which induces
Parkinsonian pathology and behavior, and how molecular
hydrogen prevents them, is discussed in this review.
2.Acute andChronicPD Model
Induced by MPTP
MPTP is a protoxin which is high lipophilic molecule, and
can penetrate the blood-brain barrier (BBB) after systemic
administration. After crossing the BBB, MPTP is readily2 Parkinson’s Disease
converted to 1-methyl-4-phenylpyridinium ion (MPP+), an
actual toxin which can lead to dopaminergic neurodegen-
eration [7]. MPTP conversion to MPP+ is dependent on
the activity of monoamine oxidase B (MAO-B) by a two-
step reaction. First, MPTP is converted to the interme-
diate 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+),
catalyzed by MAO-B [8]. Then, unstable MPDP+ dissociates
to MPP+ and MPTP [9, 10]. Conversion of MPTP to
MPDP+ occurs in glial cells and serotonergic cells, not in
dopaminergic cells. Dopaminergic neurons exhibit a high-
aﬃnity uptake process of MPP+ through the dopamine
transporter, which allows the neurotoxin MPP+ to cause
selective dopaminergic neuronal loss [11]. Inside the neu-
rons, MPP+ accumulatesin the mitochondrial matrix, whose
uptake is driven by mitochondrial transmembrane potential
gradient [12, 13]. MPP+ impairs mitochondrial respiration
by inhibiting the multisubunit enzyme complex I of the
mitochondrial electron transport chain [14, 15]. Inhibition
of complex I causes two early and major events: ATP
depletion and the buildup of reactive oxygen species (ROS).
Complex I activity appears to be decreased by more than
50% to induce nonsynaptic mitochondrial ATP depletion.
In vitro studies also revealed that mitochondria which
are isolated from whole brain require 70% inhibition of
complex I activity for ATP depletion. However, in vivo
MPTP administration causes only a transient 20% reduction
of ATP levels in mouse striatum and midbrain [16]. In
vitro experiments with synaptic mitochondria show that
exceeding a threshold of 25% inhibition of complex I results
in signiﬁcant ATP depletion [17]. These ﬁndings may imply
that synaptic mitochondria show a better correlation with
both complex I inhibition and ATP depletion than those in
somatic mitochondria. This may answer the question why
dopaminergic neurodegeneration shows retrograde degener-
ationfromstriatalnerveterminals,whicharerichinsynaptic
mitochondria.
The extents of loss of dopaminergic neurons and behav-
ioral alteration vary depending on diﬀerences in the protocol
of MPTP administration. Acute administration (20mg/kg,
3 or 4 times at 2 hours interval) can reduce ∼70% of nigral
dopaminergic neurons and ∼90% of striatal nerve terminal
ﬁbers 7 days after administration when the loss of nigral
n e u r o n si ss t a b l e[ 18] (see Table 1). Up to 10% of MPTP-
administered involuntarily die within 24 hours because of
cardiovascular side eﬀects, not of dopaminergic neuronal
loss,andmicewereimmobilizeduntil24to48hours.Striatal
MPP+ level was increased and peaked ∼3 hours after the last
administrationofMPTP.Insubacuteinjectionmodel,MPTP
is administrated once a day at 30mg/kg for 5 consecutive
days. Since mild doses of MPTP was administered compared
to the acute injection model, an incidence of death was lower
in the subacute injection model. Loss of nigral dopaminergic
neurons and striatal nerve terminal ﬁbers was also less than
acute injection model; ∼50% loss of ﬁbers and ∼40% loss
of nigral dopaminergic neurons were observed 3 weeks after
the last day of MPTP administration. For the continuous
administration model, MPTP was infused subcutaneously
(s.c.) or intraperitoneally (i.p) using osmotic pumps. Our
observation revealed that subcutaneous infusion of MPTP
at 45mg/kg/day for 28 days caused 50% loss of nigral
dopaminergic neurons [19]. Continuous administration of
MPTP subacutely or chronically caused less dopaminergic
neuronal loss, which might reﬂect sprouting of residual
ﬁbers or de novo appearance of tyrosine hydroxylase-(TH-)
positive dopaminergic neurons in DA-depleted striatum
[22–25]. Therefore, chronic recovery and damage of TH
ﬁber may occur simultaneously in nigrostriatal pathway.
The chronic administration model had several unique
features which were regarded as better phenomena as PD
model: (i) formation of inclusion bodies which were positive
for alpha-synuclein and ubiquitin, (ii) loss of noradrener-
gic (NE) neurons in locus coeruleus, (iii) impairment of
ubiquitin-proteasome system, and (iv) behavioral alteration.
Especially, loss of NE neurons was observed as in human PD
[26], and dopamine β-hydroxylase knockout (Dbh−/−)m i c e
whichlackNEneuronsshowed moreprofoundmotordeﬁcit
compared to MPTP-treated mice [27]. Furthermore, bolus
administration of MPTP did not induce inclusion bodies
formation [21]. Therefore, chronic administration model
using an osmotic pump could mimic human PD feature.
3. OxidativeDamage andApoptotic
Signals in MPTP Model
ROS, mostly a superoxide, is produced in mitochondria
because of a leak of electrons from the respiratory chain
inhibited by MPP+ [28]. Energy metabolic inhibition and
ROS overproduction have their peak several hours after
MPTP administration, which trigger the downstream of
cellular apoptosis and neurodegeneration days after MPTP
treatment [29, 30]. In PD patients, iron level is increased
selectively in SNpc, which leads to the greater accessibility
of ferrous iron (Fe2+) with hydrogen peroxide and thus
generating hydroxyl radical (•OH) [31]. Moreover, lipid per-
oxidation, protein carbonyls, and 8-oxo-7,8-dihydroguanine
(8-oxoG) are increased, which means that cellular lipids,
proteins, and DNA are highly exposed to oxidative stress
[32, 33]. Such oxidative damage occurs prior to the cellular
apoptosis processes.
Sources of ROS are various, and ROS is produced not
only in neurons but also in glial cells such as microglia when
they become activated (reactive) and show morphological
changes [34]. From dopaminergic neurons, superoxide is
produced not only in mitochondria but also by auto-
oxidation of DA [35]. It is known that auto-oxidation of
DA leads to the production of DA (semi)quinones that are
convertedintoaminochrome,whichcangeneratesuperoxide
[36,37].IncreasedROScausesoxidativedamagetoDNA[38,
39], cellular lipid peroxidation [40, 41], and stress-related
signaling activation such as MAPK and JNK activation
[42–44].
Oxidative stress in DNA leads to cellular apoptosis which
is mediated by p53 activation and p53-derived Bax translo-
cation to mitochondria. Furthermore, Bax translocation
and cytochrome c from mitochondria to the cytosol leads
to caspase-dependent apoptosis [45]. Oxidative damage in
DNA induces not only caspase-dependent apoptosis but
also caspase-independent apoptosis. Among the ﬁve normalParkinson’s Disease 3
Table 1: Comparison of representative MPTP-PD models. Each written model is representative and reproducible examples of MPTP-PD
model because many researchers modify their own protocols in creating MPTP-PD model.
Acute Sub-acute Chronic
Dose of MPTP 20mg/kg 30mg/kg 30 or 45mg/kg/day
(using osmotic pump)
Duration of MPTP 3 or 4 times at 2h interval Once a day for 5 consecutive days 28 days
Administration of MPTP i.p. i.p. i.p. (30mg)
s.c. (45mg)
Extirpation of brain 7 days after injection 21 days after injection 28 days after pump infusion
Anticipating nigral cell loss 70% 40% 50%
Anticipating striatal ﬁber loss 90% 50% 50%
Notable features Undesirable death (∼10%)
Less or no undesirable death
Nitrated α-synuclein accumulation
Behavioral alteration
(open-ﬁeld test)
Formation of inclusion bodies
(stained for α-synuclein, ubiquitin)
Loss of noradrenergic neurons
References [18, 19][ 18, 20][ 18, 19, 21]
nucleobases, guanine is the most susceptible to oxidation,
and the C8 position of free deoxyguanosine (dG) or dGTP
is the most eﬀectively oxidized by •OH in comparison to
those in DNA. In fact, eight- to nine-times more 8-oxoG is
formed in nucleotide dGTP than in DNA [46, 47]. Under
the oxidative stress condition, 8-oxoG accumulates in mito-
chondrial and nuclear DNA, which can be selectively visu-
alized by immunohistological technique [39, 48]. Systemic
MPTP administration promoted the accumulation of 8-
oxoG both in mitochondria DNA and in nuclear DNA [39].
Mitochondrial 8-oxoG (mt8oxoG) accumulated in nerve
terminal in the striatum, prior to nuclear 8-oxoG (nu8oxoG)
accumulation in nigral dopaminergic neurons. Oka et al.
[49] demonstrated that accumulation of mt8oxoG causes
mitochondrialdysfunctionresultinginATPdepletion,which
can open the mitochondrial membrane permeability tran-
sition (MMPT) pore. During replication of mitochondrial
DNA (mtDNA) with an increased level of 8-oxoG, adenine
is frequently inserted opposite 8-oxoG in mtDNA, and such
adenine paired with 8-oxoG is selectively excised by adenine
DNA glycosylase encoded by Mutyh gene. During the base
excision repair (BER) process, apurinic/apyrimidinic (AP)
endonuclease or AP lyases convert abasic sites to single-
strand breaks (SSBs) [50–53]. It has been demonstrated
that the MUTYH-initiated BER causes mtDNA degradation
resulting in its depletion under oxidative stress [49]. This
depletion may induce a decreased supply of mitochondria-
encoded proteins, transfer RNAs, and ribosomal RNAs, lead-
ing to dysfunction of mitochondrial respiration. Therefore,
accumulation of mt8oxoG results in the depletion of ATP.
Furthermore, MMPT opening enables Ca2+ to leave mito-
chondria, and cytoplasmic Ca2+ increase activates calpain,
a ubiquitous calcium-sensitive protease, thus inducing cell
death [49, 54]. It has been well documented that calpain
activation causes the cleavage of neuronal substrates that
negatively aﬀect neuronal structure and function, leading
to inhibition of essential mechanisms for neuronal survival
[55]. Moreover, inhibition of calpain is known to reduce
the dopaminergic neuronal loss in the MPTP model [56].
Taken together, we propose that oxidative stress in dopamine
neurons initiated by MPTP administration increases accu-
mulation of mt8oxoG, and thereby causes mitochondrial
dysfunction resulting in dopaminergic neuronal loss which
is dependent on the calpain pathway (Figure 1).
On the other hands, SSBs are accumulated in nuclear
DNA as a result of excision of adenine opposite nu8oxoG
by MUTYH, and activate poly (ADP-ribose) polymerase
(PARP) with the increase of poly-ADP ribosylation, leading
to nuclear translocation of apoptosis inducing factor (AIF)
and NAD/ATP depletion [49]. PARP, known as a molecular
nick-sensor, binds SSBs speciﬁcally and utilizes β-NAD+
as a substrates to catalyze the synthesis of (ADP-ribose)
polymers (poly-ADP ribosylation) on nuclear proteins,
including PARP itself with the increase of PARP activity
[57, 58]. PARP activation signal induces AIF release from
mitochondria and translocation to the nucleus, which results
in a caspase-independent pathway of programmed cell death
[59]. Activation of PARP leads to its autoconsumption, and
depletes ATP content. Therefore, a loss of energy supply
also contributes to cell death [49]. Several reports indicate
that PARP activation is associated with MPTP-derived
neurotoxicity [60, 61]. It is, however, noteworthy that
MUTYH-dependent PARP activation requires replication
of nuclear DNA [49], indicating that mitotic cells in brain
such as glial cells other than neurons may be aﬀected by the
PARP-AIF pathway with increased level of nu8oxoG. Among
glial cells, oligodendrocytes and astrocytes show PARP-AIF
pathway mediated apoptotic cell death [62, 63]. Therefore,4 Parkinson’s Disease
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Figure 1: Scheme of apoptotic death signaling by accumulation of 8-oxoguanine (8-oxoG; GO) and single-strand-breaks (SSBs) in DNA.
ROS, especially hydroxyl radical, increase the 8-oxoG accumulation and SSBs by MUTYH. In the case of SSBs in nucleus, activation of poly
(ADP-ribose)polymerase(PARP),apoptosisinducingfactor(AIF)translocationfrommitochondriatonucleus,andATPdepletionfollowed
by NAD+ depletion leads to cellular apoptosis. On the other hands, in mitochondria, accumulation of SSBs induces mitochondrial DNA
(mtDNA) degeneration. Loss of function of energy supply leads to ATP depletion, and mitochondrial membrane permeability transition
(MMPT), and calpain activation results in lysosomal rupture, which potentiates cell death (modiﬁed from Figure 8, Oka et al., 2008 [49]).
accumulation of 8-oxoG in nuDNA in glial cells may thus
cause caspase-independent cellular apoptosis, which might
play critical roles in neurodegeneration (Figure 1).
4. 6-OHDA Model andOxidativeDamage in
Nigrostriatal Neurons
For PD model animal, 6-OHDA is also used for deletion of
catecholamine in the brain and in periphery [64]. 6-OHDA
serves as a neurotoxin; which is readily auto-oxidized and
deaminated by monoamine oxidase (MAO) [65]. Because 6-
OHDA cannot penetrate blood-brain barrier, direct admin-
istration into the brain is required for the neurodegeneration
in 6-OHDA model [66]. This neurotoxin can be generated
within the brain by nonenzymatic reaction of dopamine,
hydrogen peroxide, and free iron [67–69]. Auto-oxidation
of dopamine by nitrite ions or manganese can also generate
6-OHDA [70, 71]. Oxidative damage via hydrogen perox-
ide and derived •OH are associated with the neurotoxic
mechanism by 6-OHDA [64]. The steps to generate ROS
are several varied processes: (1) in physiological condition,
6-OHDA is subjected to non-enzymatic auto-oxidation and
generatesseveraltoxicproductssuchasquinones,superoxide
anion radicals, hydrogen peroxides, and •OH [65]; (2)
Fenton reaction initiates and/or ampliﬁes ROS generation.
The deamination by MAO, or auto-oxidization increases
the hydrogen peroxide [72, 73]. Both neurotoxins, MPTP
and 6-OHDA, can potentiate the cellular apoptosis with
the increase of oxidative damage in DNA, but SSBs-derived
PARP activation does not aﬀect 6-OHDA-derived cell death
in embryonic nigral grafts [74]. This might be because
of less formation of NO in grafted nigral neurons [75].
The apoptotic mechanism by 6-OHDA is explained by the
role of p53 and Bax translocation, and caspase activation
[66].
5. Hydrogen as a Therapeutic Antioxidantfor
ExperimentalAnimalModels of PD
Since the ﬁrst striking evidence indicating that molecular
hydrogen acts as an antioxidant and inhalation of hydrogen-
containing gas reduces ischemic injury in brain [76], there
have been increasing reports which support therapeutic
properties of hydrogen against oxidative stress-related dis-
eases and damages in brain [77, 78], liver [79], intestinal
graft [80], myocardial injury [81, 82], and atherosclerosis
[83]. Hydrogen can be taken up by inhalation of hydrogen-
containing gas (hydrogen gas) or drinking hydrogen-
containing water (hydrogen water). One hour after the start
of inhalation of hydrogen gas, hydrogen can be detectable in
blood, at levels of 10μM in arterial blood [76]. The content
of hydrogen can be measured even after intake of hydrogen
water by a catheter, which shows 5μM in artery calculated
after 3min of hydrogen water incorporation [77]. Taking
into account its continuous intake, it is easier and safer to
drink hydrogen water than inhaling hydrogen gas.
We have previously reported that hydrogen in drinking
water reduced the loss of dopaminergic neurons in MPTP-
treated mice [19]. The therapeutic eﬀects of hydrogen water
against PD model have also been conﬁrmed in another
animal model, 6-OHDA-treated rats [84]. It is reported that
6-OHDA also causes 8-oxoG accumulation and mitochon-
drial dysfunction through oxidative stress [85], and thus our
model shown in Figure 1 can be applied to the PD model.Parkinson’s Disease 5
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Figure 2: The eﬀects of hydrogen in oxidative stress-derived neural apoptosis in dopaminergic cells. Hydrogen (H2) selectively reduces
hydroxyl radical (•OH) by direct reaction, and decreased oxidative damage such as mitochondrial/nuclear 8-oxoG (mt8oxoG/nu8oxoG)
accumulation, and 4-hydroxynonenal (4-HNE) production in dopaminergic neurons. Each oxidative damage is involved in diﬀerent
neuronal apoptosis. Abbreviation; MPP+: 1-methyl-4-phenylpyridinium ion, DAT: dopamine transporter, ROS: reactive oxygen species,
ATP: adenosine 5 -triphosphate, •OH: hydroxyl radical, •O2
−: superoxide, 4-HNE: 4-hydroxynonenal.
In these animal models, a number of dopaminergic
neurons in SNpc, as well as nerve terminal ﬁbers in stria-
tum, were decreased by administration of the neurotoxin.
However, hydrogen water signiﬁcantly reduces the loss of
both neuronal cell bodies and ﬁbers compared with normal
water. In MPTP-treated mice, chronic administration using
an osmotic minipump results in neuronal loss as well as
behavioral impairments observed by the open-ﬁeld test
[21]. Rats administered with 6-OHDA also show behav-
ioral impairments assessed by the rotarod test. Hydrogen
improved behavioral impairment in both MPTP and 6-
OHDA model. From these observations, hydrogen water
even prevents behavioral alteration which is regarded as a
major symptom in PD.
It would provide us with useful information for the
design of a therapeutic strategy to investigate how long
the neuroprotection acquired by hydrogen water lasts.
Continuous intake of hydrogen water before and during
MPTP administration showed signiﬁcant neuroprotection.
However, intake of hydrogen water even after MPTP
administration also reduced neurotoxic damage [19]. PD
is regarded as a progressive neurodegenerative disease, so
daily intake of hydrogen water might prevent the disease
progression as well as the onset of neurodegeneration.
It has been reported that hydrogen reduced cytotoxic
•OH selectively whereas the production of other radicals
such as superoxide, hydrogen peroxide and nitric oxide was
not altered by hydrogen [76]. This selectivity was proved
by cell-free system, and in particular, the preference of
scavenging of •OH rather than superoxide was conﬁrmed
in PC12 cell culture system [76]. According to Setsukinai et
al. [86], both •OH and peroxynitrite (ONOO−)w e r em u c h
more reactive than other ROS. This would be an answer why
hydrogen shows selective reaction with only the strongest
radicals both in the cell-free system and in PC12 cells.
Especially, •OH overproduction in oxidative and neu-
rotoxic reaction by MPTP leads to lipid peroxidation
observed by 4-hydroxynonenal (4-HNE) immunostaining
in nigral dopaminergic neurons prior to cellular death. 4-
HNE immunoreactivity in MPTP-treated mice is increased
by three-times as much as in saline-treated mice [19], which
was similar to the previous report of 4-HNE protein levels in
substantia nigra observed at the same periods after MPTP
administration using HPLC [41]. Hydrogen water signiﬁ-
cantly reduces the formation of 4-HNE in dopaminergic
neurons in the substantia nigra to the level of control [19]
(Figure 2). On the other hand, the increase of superoxide,
which is detectable by administration of dihydroethidine
(DHE) intravenously, was not signiﬁcantly reduced by
hydrogen water [19]. Although hydrogen reduces the pro-
duction of superoxide in brain slices in hypoxia/reperfusion
injury [87], hydrogen water might show a preferential
reduction of •OH during the protection of dopaminergic
neurons.
Hydrogen water signiﬁcantly reduces the accumulation
of 8-oxoG in striatum after MPTP administration [19]
(Figure 2). As mentioned above, 8-oxoG, an oxidized form
of guanine, accumulates both in mitochondria and in6 Parkinson’s Disease
nucleus; their nomenclature are mt8oxoG and nu8oxoG,
respectively. Mt8oxoG accumulates in striatum which are
rich in mitochondria in nerve terminal of dopaminergic
neurons projected from the substantia nigra. Although
nu8oxoG was not detected in nigral cell nucleus [19],
hydrogenwatermightpreventthemt8oxoG-inducedcellular
apoptotic signals, not just reduce •OH in dopaminergic
nerve terminals.
Hydrogen was eﬀectivewhenitwasinhaledduringreper-
fusion; when hydrogen was inhaled just during ischemia
(not in reperfusion), infarct volume was not signiﬁcantly
decreased [76]. It was shown that hydrogen in the brain
decreased immediately after stopping inhalation and com-
pletely disappeared within 10min [19], indicating that the
eﬀect of hydrogen can be observed only during the period
whentheoxidativeinsultsoccur.Hydrogencouldbedetected
in the blood 3min after administration of hydrogen water
into the stomach [77]. However, unpublished data showed
that the half-life of hydrogen in the muscle in rats was
approximately 20min after the administration of hydrogen
gas. Taking these reports into consideration, hydrogen in
the brain and other tissues does not stay long enough to
exert its ability as an antioxidant to ROS directly. Therefore,
it is unlikely that direct reaction of hydrogen itself with
ROS plays a major role in the neuroprotection, especially
by hydrogen in drinking water, although hydrogen itself has
the ability to reduce •OH preferentially. In accordance with
this hypothesis, previous reports from Nakao et al. [88]
has demonstrated that drinking hydrogen water increases
urinary antioxidant enzyme, superoxide dismutase (SOD),
an endogenous defensive system against ROS- (especially
superoxide-) mediated cellular damage. Although it takes
eight weeks for signiﬁcant increase of SOD in humans,
hydrogen has the ability to alter the expression level of
urinary antioxidant enzyme. It was also reported that hydro-
gen water increased total bilirubin for four to eight weeks
compared to baseline. Bilirubin is produced by the catalytic
reaction of heme oxygenase 1 (HO-1), and degradation of
heme generates bilirubin as well as carbon monoxide and
free iron. The increase of HO-1 expression is likely due to
the response to oxidative stress, and this response is also
characterized as a phase II antioxidant which is positively
regulated by several stress-responsive transcriptional factors
[89]. Therefore, taking these observations into account, we
might better have another aspect for protective eﬀect of
hydrogenindrinking waterapartfrominhalation. Itis possi-
blethatdrinkingofhydrogenwaterhasnotonlytheabilityto
reduce cytotoxic radicals, but also novel mechanisms which
are related to anti-oxidative defense system.
6. Conclusion
Oxidative stress is a key factor to induce cellular apoptosis
in MPTP- and 6-OHDA-derived neurotoxicity. From studies
using postmortem human brain of PD patients, increased
iron, oxidation of proteins and DNA, lipid peroxidation
in the SN appear to be important ﬁndings of oxidative
stress [90–93]. Thought there are eﬀective antioxidants or
therapeutic strategies for PD, reduction of oxidative stress
would be more desirable to attenuate neurotoxic damage in
PD. Here, we would like to address that one of the most
eﬃcient ways to attenuate oxidative stress is taking low con-
centration of hydrogen in drinking water, a safer and easier
way of hydrogen intake. Although the precise mechanism
how hydrogen works is still under investigation, it will be
possible to reveal the mechanisms using conventional PD
models such as MPTP and 6-OHDA models. Not only that
it is of great interest to know the neuroprotective mechanism
of hydrogen but also hydrogen will bring great beneﬁcial
eﬀects to reduce a risk of lifestyle-related oxidative damage
and related neurodegenerative diseases including PD.
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